PMID- 15538111
OWN - NLM
STAT- MEDLINE
DCOM- 20050315
LR  - 20191210
IS  - 1052-9551 (Print)
IS  - 1052-9551 (Linking)
VI  - 13
IP  - 4
DP  - 2004 Dec
TI  - Feasibility of using tissue microarrays for the assessment of HER-2 gene 
      amplification by fluorescence in situ hybridization in breast carcinoma.
PG  - 213-6
AB  - Tissue microarrays (TMAs) have been commonly used to study protein expression by 
      immunohistochemistry (IHC). However, limited data exist on the validity of using 
      TMAs to study gene amplification. In this study, we evaluated the feasibility of 
      using breast carcinoma TMAs to study HER-2 gene amplification by fluorescence in 
      situ hybridization (FISH). In addition, hormonal receptor status (ER and PR) and 
      HER-2 protein overexpression by IHC were also studied, and results were compared 
      with whole tissue sections. FISH for HER-2 was performed on formalin-fixed 
      paraffin-embedded tissue from 114 invasive breast carcinomas both on whole tissue 
      sections and on TMAs containing the same tumors. The TMA was created using 0.6-mm 
      tissue cores with four sampled cores per tumor from the same tissue block used 
      for whole section FISH. The PathVysion HER-2 probe kit was used for the FISH 
      analysis. A ratio of HER-2:Chromosome17 > or =2.0 was interpreted as positive for 
      gene amplification. The ER or PR was interpreted as positive when nuclear 
      staining was detected in more than 10% of tumor cells. The HER-2 IHC (HercepTest; 
      DAKO Corp, Carpinteria, CA) results were interpreted as 0, 1+, 2+, and 3+ 
      according to standard criteria. The FISH results in the TMA and whole sections 
      were concordant in 99 out of 101 successfully analyzed cases (99%). The FISH 
      scores were consistent among the two to four cores in the majority of the cases. 
      ER and PR results were concordant between whole sections and TMA cores in 97% 
      (107/110) and 89% (97/109) cases, respectively. The overall concordance for HER-2 
      status by IHC between whole sections and TMA cores was 86% (94 out of 109 cases). 
      TMAs are a reliable approach to study HER-2 gene amplification in a high 
      throughput manner.
FAU - Bhargava, Rohit
AU  - Bhargava R
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 
      10021, USA.
FAU - Lal, Priti
AU  - Lal P
FAU - Chen, Beiyun
AU  - Chen B
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Diagn Mol Pathol
JT  - Diagnostic molecular pathology : the American journal of surgical pathology, part 
      B
JID - 9204924
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/pathology
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Cell Nucleus/metabolism
MH  - Feasibility Studies
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Oligonucleotide Array Sequence Analysis/*methods
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Reproducibility of Results
EDAT- 2004/11/13 09:00
MHDA- 2005/03/16 09:00
CRDT- 2004/11/13 09:00
PHST- 2004/11/13 09:00 [pubmed]
PHST- 2005/03/16 09:00 [medline]
PHST- 2004/11/13 09:00 [entrez]
AID - 00019606-200412000-00003 [pii]
AID - 10.1097/01.pdm.0000140195.05428.1d [doi]
PST - ppublish
SO  - Diagn Mol Pathol. 2004 Dec;13(4):213-6. doi: 10.1097/01.pdm.0000140195.05428.1d.